AN2 Therapeutics (ANTX) Return on Equity (2021 - 2026)

AN2 Therapeutics (ANTX) has 6 years of Return on Equity data on file, last reported at 0.01% in Q1 2026.

• Return on Equity for Q1 2026 came in at 0.01%, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.01% (changed 0.0% YoY), and the FY2025 annual result was 0.01%, changed 0.0% from the prior year.
• Return on Equity improved to 0.01% in Q1 2026 per ANTX's latest filing, from 0.01% in the prior quarter.
• Over five years, Return on Equity peaked at 0.0% in Q2 2022 and troughed at 0.01% in Q1 2022.
• A 5-year average of 0.01% and a median of 0.01% in 2023 frame the typical range for Return on Equity.
• The sharpest annual moves came in 2022 and 2023: Return on Equity decreased 1 bps in 2022, then changed 0 bps in 2023.
• A 5-year view of Return on Equity shows it stood at 0.0% in 2022, then decreased by 30 bps to 0.01% in 2023, then dropped by 15 bps to 0.01% in 2024, then retreated by 2 bps to 0.01% in 2025, then climbed by 17 bps to 0.01% in 2026.
• Business Quant data shows ANTX's Return on Equity at 0.01% in Q1 2026, 0.01% in Q4 2025, and 0.01% in Q3 2025.